Table 2.
Echocardiographic measures
| Control | Exercise | PhAm | ExPhAm | |||||
|---|---|---|---|---|---|---|---|---|
| B | EOS | B | EOS | B | EOS | B | EOS | |
|
| ||||||||
| EDV(ul) | 52.33 ± 7.6 | 45.18 ± 5.84 | 53.43 ± 7.4 | 44.9 ± 3.99 | 56.28 ± 15.0 | 49.92 ± 12.97 | 49.8 ± 6.0 | 46.5 ± 6.14 |
| ESV(ul) | 23.25 ± 5.1 | 17.7 ± 3.95 | 22.73 ± 5.1 | 17.78 ± 2.79 | 24.23 ± 10.4 | 16.82 ± 6.25 | 20.23 ± 3.7 | 19.83 ± 4.69 |
| SV(ul) | 29.08 ± 4.2 | 27.48 ± 2.88 | 30.73 ± 3.6 | 27.14 ± 1.28 | 32.00 ± 6.7 | 33.07 ± 7.46 a | 29.55 ± 3.5 | 26.68 ± 3.44 |
| FS (%) | 31.43 ± 5.0 | 37.57 ± 3.25 | 30.70 ± 7.7 | 33.88 ± 5.6 | 32.6 ± 6.7 | 40.02 ± 8.37 | 31.4 0± 4.0 | 30.02 ± 10.94 |
| CO (ml/min) | 15.05 ± 2.5 | 14.58 ± 1.37 | 14.85 ± 1.9 | 13.16 ± 0.89 | 16.82 ± 2.7 | 17.3 ± 4.1 b | 15.15± 1.18 | 14.1 ± 1.71 |
| GLS (%) | −18.26 ± 3.1 | −17.42 ± 2.89 | −19.56 ± 1.9 | −18.1 ± 3.63 | −20.68 ± 2.5 | −22.73 ± 3.62 c | −20.75 ± 2.3 | −18.34 ±2.93 |
| EF (%) | 55.67 ± 5.7 | 60.83 ± 4.4 | 57.83 ± 5.2 | 60.4 ± 2.88 | 57.83 ± 8.1 | 67 ± 6.42 a | 59.00 ± 4.3 | 57.33 ± 6.47 |
| EDLVM | 57.33 ± 5.8 | 69 ± 17.08 | 83.17 ± 17.9 | 61.4 ± 12.05 | 61.33 ± 10.5 | 61.67 ± 12.14 | 66.17 ± 7.9 | 59.17 ± 4.07 |
| ESLVM | 54.83 ± 7.1 | 62.17 ± 13.93 | 81.17 ± 17.4 | 57.6 ± 12.26 | 61.00 ± 11.2 | 59.33 ± 13.43 | 65.00 ± 8.7 | 53.83 ± 6.71 |
| Heart Rate (bpm) | 517.7 ± 44.00 | 531.73 ± 25.43 | 483.4 ± 32.9 | 486.08 ± 24.37 | 530.42 ± 33.9 | 523.88 ± 47.4 | 515.88 ± 29.2 | 527.82 ± 8.39 |
| LV Mass (mg) | 63.09 ± 3.52 | 72.56 ± 4.98 | 62.97 ± 7.0 | 69.03 ± 5.45 | 56.42 ± 11.7 | 64 ± 12.47 | 58.70 ± 5.8 | 63.73 ± 9.41 |
| LV/BM Index (%) | 2.88 ± 0.5 | 2.54 ± 0.26 | 2.40 ± 0.2 | 2.49 ± 0.14 | 2.45 ± 0.5 | 2.28 ± 0.39 | 2.44 ±0.1 | 2.46 ± 0.31 |
Data are mean ± standard deviatoin. B, Baseline; EOS, End of Study; PhAm, phellodendrun amurense; ExPhAm, exercise with phellodendrun amurense;
p≤0.01 compared to ExPhAm,
p<0.05 compared to exercise,
p<0.05 compared to control.